Clinical trial / 2008
Potassium supplementation for 28 days reduced pain intensity in hypokalemic women with active rheumatoid arthritis.
Thirty-two hypokalemic women with active rheumatoid arthritis were randomized to receive their usual medication plus either placebo or 6,000 mg potassium chloride dissolved in grape juice daily for 28 consecutive days. At day 28, 43.75% (7/16) of patients in the potassium group met the criteria for a 33% reduction in pain intensity compared with 6.25% (1/16) in the placebo group (P < .02). Additionally, 31.25% (5/16) of patients receiving potassium achieved a EULAR moderate response compared to 6.25% (1/16) in the placebo group (P < .05). Elevated serum cortisol and potassium values in the treatment group correlated negatively with pain intensity.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 32 female hypokalemic patients with active rheumatoid arthritis (mean age 48.6 +/- 6 years)
- What was measured
- Change of pain on a visual analog scale (VAS), ACR percent response criteria, DAS28, and EULAR moderate response
THE PAPER
A pilot study of potassium supplementation in the treatment of hypokalemic patients with rheumatoid arthritis: a randomized, double-blinded, placebo-controlled trial.
Rastmanesh R, Abargouei AS, Shadman Z, Ebrahimi AA, Weber CE. J Pain, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.